On July 30, 2015 TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and Jiangsu Hengrui Medicine Co., Ltd., a fully integrated pharmaceutical company based in China, reported an exclusive license agreement for the development, registration, manufacture, and commercialization of rolapitant in China (Press release, TESARO, JUL 30, 2015, View Source [SID:1234506756]). Schedule your 30 min Free 1stOncology Demo! Hengrui will make upfront and milestone payments to TESARO subject to the achievement of certain events, in addition to royalty payments on annual net sales in China. Additional financial details were not disclosed.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"TESARO is committed to advancing new therapeutic options for patients with cancer, and we are pleased to be working with Hengrui to develop and commercialize rolapitant for patients in China," said Lonnie Moulder, CEO of TESARO. "Hengrui is a leading innovative pharmaceutical company in China, with a substantial portfolio of marketed oncology products, deep regulatory expertise, and a robust pipeline of product candidates. With a strong commitment to quality and a significant level of expertise in clinical development, regulatory affairs, and commercialization, we believe Hengrui is the optimal partner to develop rolapitant in China."
Piaoyang Sun, Chairman of the Board of Hengrui, added, "As one of the leading pharmaceutical companies in China, Hengrui has a rich history of delivering high quality oncology products worldwide and continues to be committed to developing innovative oncology medicines. In recent years, Hengrui has expanded its oncology portfolio to include cancer supportive care products, and the development and commercialization of rolapitant for China is the most recent example of our effort to make new therapeutic options available to millions of cancer patients here. We are extremely pleased to be working with TESARO, an emerging leader in the development of oncology specialty medicines."
Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). The New Drug Application (NDA) for oral rolapitant is currently under review by the U.S. Food and Drug Administration, with a PDUFA goal date of September 5, 2015. Rolapitant has not been approved by any regulatory agency.